Fresh analysis reveals that individuals who stop using new slimming jabs like Mounjaro or Wegovy may regain reduced body mass far faster than those who stop conventional lifestyle regimens.
Published data in a leading health publication shows that while obese people often shed about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Users buying such treatments should be informed of the danger of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment mass within about 18 months.
Weighing Approaches
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
The team emphasize that individuals who lose weight through diet and exercise typically have a more gradual creep back—around 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Experts propose the mode of action of the jabs accounts for the heightened weight return.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating far more likely."
An Ongoing Issue?
The NHS suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians argue that, due to the high risk of weight regain, the therapy might need to be life-long.
This perspective is reinforced by pharmaceutical companies, who state that the results "emphasize the chronic character of obesity," comparing it to managing diseases like diabetes.
User Accounts
Individuals who have stopped the jabs describe a powerful resurgence of cravings.
"It was like a trigger that goes on and you're instantly extremely hungry," said one woman.
This challenge is worsened if individuals have not established lasting dietary or behavioural modifications during treatment.
Significant Use
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and lasting health benefits hinges on integrated lifestyle management.
